



Building Strong Partnerships

Mochida Pharmaceutical actively engages in alliances with external partners to ensure that we deliver new medications that improve patients' lives. Our partnerships extend from research to marketing, and we value highly these alliances of excellence as we take on challenges together to satisfy unmet medical needs.



Collaboration with Other Companies

Mochida Pharmaceutical prioritizes cardiovascular, obstetrics and gynecology, dermatology, and emergency medicine in its sales resource allocation for its core pharmaceutical business. We are strengthening our product pipeline, maximizing product value, and advancing the development of high-value-added products to meet medical treatment needs and customer needs through numerous domestic and international partnerships.

For example, *Atelec*[®], the long-acting calcium channel antagonist antihypertensive drug licensed by Ajinomoto Co., Inc., has achieved double-digit growth every year for more than a decade. Mochida Pharmaceutical has also developed and launched *Beselna Cream*, a condyloma acuminatum treatment licensed by iNova Pharmaceuticals (Australia) Pty Limited, and *Dinigest*, an oral progestin for the treatment of endometriosis licensed by Bayer Schering Pharma AG.

We are also working on the development of drugs for intractable diseases, including the pulmonary hypertension treatment under an exclusive distribution license from United Therapeutics Corporation and the ulcerative colitis treatment licensed by Shire Pharmaceuticals Group (U.K.).

In biomedicine, Mochida Pharmaceutical is jointly developing Japan's first therapeutic cellular-based drug together with JCR Pharmaceuticals Co., Ltd., and advancing joint development of a biosimilar G-CSF together with Fuji Pharma.

We are also seeking a marketing approval of an OTC version of our major ethyl icosapentate (EPA-E) product, *Epadel*, and have concluded a distribution agreement with Taisho Pharmaceutical Co., Ltd. Through collaboration with our valuable partners, Mochida Pharmaceutical continues fulfilling our mission of providing pharmaceutical products to meet unmet medical needs.

